Nautilus Biotech Announces IND Filing for Belerofon®, Its Oral, Long-lasting, Interferon-alpha Drug
3/2/2007 6:17:25 PM
Paris, France, 27 February 2007, Nautilus Biotech has announced that it has submitted an Investigational New Drug (IND) filing to the US Food and Drug Administration (FDA) for oral Belerofon®, its long-lasting human Interferon (IFN) alpha. Belerofon has therapeutic potential for the treatment of a number of conditions, including chronic Hepatitis C. The new drug will be administered orally - all currently marked interferon alpha drugs are administered by injection - resulting in improved safety and patient compliance.
comments powered by